Eli Lilly's Abemaciclib: Better Than Competition In Breast Cancer?
It is difficult to assess which drug, if any, will win out, except that Abemaciclib has a different safety profile from the competition. Eli Lilly is developing Abemaciclib for a number of indications including in Hormone-Receptor-Positive , HER2-negative metastatic breast cancer.
from Biotech News
0 Comments